skip to Global Navigation Bar skip to main content

homeHome > R&D

Daewoong seeks committed, long-term global R&D partners who possess world-class technology for the development of globally competitive pharmaceuticals.


Category Details
New Chemical Entities Diabetes Fibrosis (e.g. liver, lung, renal) Ion channel drug targets, candidates or platforms
Biologics Cancer specific antibodies (monoclonal, bispecific) Immune checkpoint blockades Non-Antibody Alternative scaffolds Stem cell research collaboration (mainly with Korean partners)
DDS Sustained release technologies e.g. long-acting injectables Osmotic pump systems (zero order systems) Nanoparticles
API Chiral synthesis platform technologies for API Value added APIs : New salt, polymorphism